TCGA-75-6206-01A-11R-1755-07
— · cohortA2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA2
- subtype
- cohortA2
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.450
- PROTEIN_SECRETION+0.380
- UV_RESPONSE_DN+0.270
- ADIPOGENESIS+0.260
- HEDGEHOG_SIGNALING+0.260
- XENOBIOTIC_METABOLISM+0.230
- HEME_METABOLISM+0.200
- BILE_ACID_METABOLISM+0.190
- COAGULATION+0.190
- WNT_BETA_CATENIN_SIGNALING+0.180
Top 10 suppressed
- E2F_TARGETS-0.600
- G2M_CHECKPOINT-0.550
- MTORC1_SIGNALING-0.390
- MYC_TARGETS_V1-0.360
- MYC_TARGETS_V2-0.310
- SPERMATOGENESIS-0.290
- ALLOGRAFT_REJECTION-0.210
- APICAL_SURFACE-0.210
- DNA_REPAIR-0.200
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-62-8395-01A-11R-2326-07 | — | cohortA2 | 0.876 |
| 2 | TCGA-97-7547-01A-11R-2039-07 | — | cohortA1 | 0.848 |
| 3 | TCGA-05-4384-01A-01R-1755-07 | — | cohortA2 | 0.843 |
| 4 | TCGA-44-6146-01A-11R-1755-07 | — | cohortA1 | 0.829 |
| 5 | TCGA-97-7938-01A-11R-2170-07 | — | cohortA1 | 0.796 |
| 6 | TCGA-97-8174-01A-11R-2287-07 | — | cohortA2 | 0.796 |
| 7 | SRR6013580 | — | cohortA2 | 0.790 |
| 8 | TCGA-GD-A3OP-01A-21R-A220-07 | — | — | 0.788 |
| 9 | TCGA-86-8056-01A-11R-2241-07 | — | cohortA1 | 0.785 |
| 10 | TCGA-67-3774-01A-01R-0946-07 | — | cohortA2 | 0.778 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.450 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.380 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.270 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.260 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.260 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.230 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.200 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| COAGULATION | 0.190 | Binimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.180 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.170 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.170 | Inavolisib | — uncovered |
| PEROXISOME | 0.110 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.080 | Inavolisib | — uncovered |
| MYOGENESIS | 0.080 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.040 | Cobimetinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.040 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.040 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.030 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.020 | Inavolisib | — uncovered |